FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 278 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients... May 7, 2026 Investing in volunteers since 2002: The tale of time July 11, 2022 No Glucose? Pancreatic Cancer May Have a Ready Energy Alternative June 22, 2023 HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... September 13, 2023 Load more HOT NEWS Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or... FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... Her Mother Died of Breast Cancer When She Was Five. 16... FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer
